Literature DB >> 14675805

Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder.

Oliver Pogarell1, Christine Hamann, Gabriele Pöpperl, Georg Juckel, Martina Choukèr, Michael Zaudig, Michael Riedel, Hans-Jürgen Möller, Ulrich Hegerl, Klaus Tatsch.   

Abstract

BACKGROUND: A central serotonergic dysfunction is considered to be involved in the pathophysiology of obsessive-compulsive disorder (OCD). The aim of this study was to investigate the serotonin transporter availability in patients with OCD as an in vivo marker of the central serotonergic system.
METHODS: Nine unmedicated (7 drug-naive) patients with OCD and 10 healthy control subjects were included and received single photon emission computed tomography (SPECT) 20.75 +/- 1.51 hours after injection of a mean 147.20 +/- 6.74 MBq [(123)I]-2beta-carbomethoxy-3beta-(4-iodophenyl)tropane ([(123)I]beta-CIT). As a measure of brain serotonin transporter availability, a ratio of specific-to-nonspecific [(123)I]beta-CIT binding for the midbrain-pons (V(3)" = [midbrain/pons-occipital]/occipital) was used.
RESULTS: Mean specific-to-nonspecific ratios showed a 25% higher midbrain-pons [(123)I]beta-CIT binding in the patients as compared with healthy controls (2.26 +/-.37 vs. 1.81 +/-.23, p <.01). The difference remained significant after adjustment for clinical variables and controlling for age and gender. Stratification of the patients according to onset of the disorder revealed significant differences between controls and patients with early (childhood, adolescence) but not late (adult) onset of OCD.
CONCLUSIONS: The study provides evidence of a serotonergic dysfunction in patients with OCD and suggests a serotonergic component in the pathophysiology of the disorder.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14675805     DOI: 10.1016/s0006-3223(03)00183-5

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  28 in total

1.  Central serotonin transporter levels are associated with stress hormone response and anxiety.

Authors:  Matthias Reimold; Astrid Knobel; Michael A Rapp; Anil Batra; Klaus Wiedemann; Andreas Ströhle; Anke Zimmer; Peter Schönknecht; Michael N Smolka; Daniel R Weinberger; David Goldman; Hans-Jürgen Machulla; Roland Bares; Andreas Heinz
Journal:  Psychopharmacology (Berl)       Date:  2010-06-29       Impact factor: 4.530

2.  Increased orbitofrontal cortex activation associated with "pro-obsessive" antipsychotic treatment in patients with schizophrenia.

Authors:  Frederike Schirmbeck; Daniela Mier; Christine Esslinger; Franziska Rausch; Susanne Englisch; Sarah Eifler; Andreas Meyer-Lindenberg; Peter Kirsch; Mathias Zink
Journal:  J Psychiatry Neurosci       Date:  2015-03       Impact factor: 6.186

Review 3.  Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature.

Authors:  Trehani M Fonseka; Margaret A Richter; Daniel J Müller
Journal:  Curr Psychiatry Rep       Date:  2014-11       Impact factor: 5.285

4.  Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder.

Authors:  Xian-Zhang Hu; Robert H Lipsky; Guanshan Zhu; Longina A Akhtar; Julie Taubman; Benjamin D Greenberg; Ke Xu; Paul D Arnold; Margaret A Richter; James L Kennedy; Dennis L Murphy; David Goldman
Journal:  Am J Hum Genet       Date:  2006-03-28       Impact factor: 11.025

Review 5.  [Neurobiology of obsessive-compulsive disorder].

Authors:  S Karch; O Pogarell
Journal:  Nervenarzt       Date:  2011-03       Impact factor: 1.214

6.  [123I] ADAM brainstem binding correlates with the loudness dependence of auditory evoked potentials.

Authors:  Oliver Pogarell; Walter Koch; Nadine Schaaff; Gabriele Pöpperl; Christoph Mulert; Georg Juckel; Hans-Jürgen Möller; Ulrich Hegerl; Klaus Tatsch
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-11-07       Impact factor: 5.270

7.  Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity - a [11C]DASB PET study.

Authors:  M Reimold; M N Smolka; A Zimmer; A Batra; A Knobel; C Solbach; A Mundt; H U Smoltczyk; D Goldman; K Mann; G Reischl; H-J Machulla; R Bares; A Heinz
Journal:  J Neural Transm (Vienna)       Date:  2007-08-22       Impact factor: 3.575

8.  Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET.

Authors:  Dean F Wong; James R Brasić; Harvey S Singer; David J Schretlen; Hiroto Kuwabara; Yun Zhou; Ayon Nandi; Marika A Maris; Mohab Alexander; Weiguo Ye; Olivier Rousset; Anil Kumar; Zsolt Szabo; Albert Gjedde; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2007-11-07       Impact factor: 7.853

9.  123I-ADAM SPECT imaging of serotonin transporter binding in patients with night eating syndrome: a preliminary report.

Authors:  Jennifer D Lundgren; Andrew B Newberg; Kelly C Allison; Nancy A Wintering; Karl Ploessl; Albert J Stunkard
Journal:  Psychiatry Res       Date:  2008-02-20       Impact factor: 3.222

10.  [I-123] ADAM and SPECT in patients with borderline personality disorder and healthy control subjects.

Authors:  Walter Koch; Nadine Schaaff; Gabriele Pöpperl; Christoph Mulert; Georg Juckel; Markus Reicherzer; Christoff Ehmer-von Geiso; Hans-Jürgen Möller; Ulrich Hegerl; Klaus Tatsch; Oliver Pogarell
Journal:  J Psychiatry Neurosci       Date:  2007-07       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.